These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25502412)

  • 1. Molecular modelling studies of sirtuin 2 inhibitors using three-dimensional structure-activity relationship analysis and molecular dynamics simulations.
    Chuang YC; Chang CH; Lin JT; Yang CN
    Mol Biosyst; 2015 Mar; 11(3):723-33. PubMed ID: 25502412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
    Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
    J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
    Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
    Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hit evaluation results in 5-benzyl-1,3,4-thiadiazole-2-carboxamide based SIRT2-selective inhibitor with improved affinity and selectivity.
    Gozelle M; Kaya SG; Aksel AB; Ozkan E; Bakar-Ates F; Ozkan Y; Eren G
    Bioorg Chem; 2022 Jun; 123():105746. PubMed ID: 35358824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
    Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
    J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling study for conformational changes of Sirtuin 2 due to substrate and inhibitor binding.
    Sakkiah S; Chandrasekaran M; Lee Y; Kim S; Lee KW
    J Biomol Struct Dyn; 2012; 30(3):235-54. PubMed ID: 22694102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking and dynamics simulation, receptor-based hypothesis: application to identify novel sirtuin 2 inhibitors.
    Sakkiah S; Thangapandian S; Park C; Son M; Lee KW
    Chem Biol Drug Des; 2012 Aug; 80(2):315-27. PubMed ID: 22564257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual screening approach of sirtuin inhibitors results in two new scaffolds.
    Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M
    Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations.
    Sakkiah S; Arooj M; Kumar MR; Eom SH; Lee KW
    PLoS One; 2013; 8(1):e51429. PubMed ID: 23382805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
    Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
    ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
    Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
    J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR studies on the human sirtuin 2 inhibition by non-covalent 7,5,2-anilinobenzamide derivatives.
    Ferreira GM; Magalhães JG; Maltarollo VG; Kronenberger T; Ganesan A; Emery FDS; Trossini GHG
    J Biomol Struct Dyn; 2020 Feb; 38(2):354-363. PubMed ID: 30789810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
    Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
    Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations.
    Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U
    Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.
    Wang F; Yang W; Shi Y; Le G
    J Biomol Struct Dyn; 2015 Sep; 33(9):1929-40. PubMed ID: 25341687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.